Sylics was acquired by InnoSer. To see what’s new, read below or use the navigation bar to find the information you need.

    Parkinson’s Disease Mouse Models

    Perform in vivo efficacy studies using one of InnoSer’s Parkinson’s Disease Mouse Models

    Home » Neurology CRO Services » Parkinson’s Disease Mouse Models

    As a European preclinical neurology contract research organization (CRO), InnoSer provides you with a portfolio of Parkinson’s disease mouse models that are relevant for performing preclinical efficacy research studies. By choosing InnoSer as your partner CRO, you will work alongside our expert study directors who take a collaborative approach for your study, accommodating your study timelines and budget needs.  InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, gene therapy (viral vectors – e.g.. AAVs) and immunotherapies (antibody/vaccine immunotherapies). 

    InnoSer offers multiple Parkinson’s disease mouse models for preclinical research, including MPTP mouse model of Parkinson’s disease, and transgenic alpha-synuclein or seeding alpha synuclein mouse models using recombinant and/or patient-derived seeds. However, as each model is unique, modelling distinct pathophysiological aspects of Alzheimer’s disease, we recommend you discuss the most appropriate model with our neurology study directors. 

    Parkinson’s Disease Mouse Models options

    MPTP Mouse Model of Parkinson's Disease

    InnoSer offers unique services using MPTP-based inducible PD models.

    NLRP3 Inflammasome Activation Model

    Target neuroinflammation in Parkinson’s disease by studying the therapeutic effects on the NLRP3 pathway activation. 

    Seeding Alpha-Synuclein Models

    InnoSer has extensive experience with α-syn seeding using both PD patient-derived brain extracts and recombinant seeds.

    Transgenic Alpha-Synuclein Models

    InnoSer offers fee-for-service transgenic α-syn mouse models.
    Preclinical behavioral test for drug development

    Rodent Behavioral Testing Made Simple.

    Explore our extensive portfolio of validated and tailored behavioral and cognitive rodent tests designed to advance your research.

    Parkinson’s Disease 

    Brain pathology: alpha-synuclein and substantia nigra degeneration

    Parkinson’s disease (PD) is characterized by specific hallmarks observed in post-mortem brain tissue, including the presence of intracellular inclusions called Lewy bodies, consisting of the protein alpha-synuclein (α-syn), and cell death in the substantia nigra (SN). These Lewy bodies and SN degeneration are linked to the motor symptoms, but at later stages, both α-syn inclusions and neurodegeneration spread throughout the brain.

    Key events contributing to the neurodegeneration and clinical symptoms in PD are believed to involve lysosomal dysfunction, the spreading of α-syn aggregates, and neuroinflammation. Various mouse models of PD have been developed to replicate these disease mechanisms effectively.

    Tyrosine hydroxylase staining can be used to assess dopaminergic cell loss after localized lesions in the substantia nigra.

    Tyrosine hydroxylase staining can be used to assess dopaminergic cell loss after localized lesions in the substantia nigra.

    European based preclinical CRO offering SOD1 model transgenic parkinson's disease mouse models for drug development

    Risk factors: SNCA, LRRK2, GBA

    Mutations in the genes SNCA, LRRK2, and GBA have significant implications in both familial and sporadic forms of Parkinson’s disease (PD). SNCA is responsible for encoding the alpha-synuclein protein, providing further evidence of its pivotal role in PD. Meanwhile, LRRK2 and GBA encode proteins crucial for intracellular clearance pathways.

    Mouse models that replicate these genetic risk factors offer valuable insights into PD and serve as attractive models for studying the disease. These models present an opportunity to test potential treatments for Parkinson’s disease and advance our understanding of its underlying mechanisms.

    The people behind the models

    Jolien Beekens, PhD

    Jolien Beekens, PhD, Neurology Study Director

    With in vitro screening methods available as a suited first step in your development process our team of experts have the experience to optimise your study design process.

    Thomas Vogels, PhD Neurology study director InnoSer

    Thomas Vogels, PhD, Neurology Study Director

    Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.

    AAALAC Accreditation

    InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

    AAALAC logo

    Animal Welfare

    The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

    Related Resources

    View our in vivo neurology models overview with sample data

    In Vitro & In Vivo Parkinson’s Disease Models: Understanding Their Role in Preclinical Drug Development

    Neurology research models and services overview page